Previous Close | 136.32 |
Open | 136.10 |
Bid | 136.14 x 30000 |
Ask | 136.48 x 30000 |
Day's Range | 136.10 - 136.80 |
52 Week Range | 132.74 - 160.40 |
Volume | |
Avg. Volume | 1,053 |
Market Cap | 329.234B |
Beta (5Y Monthly) | 0.53 |
PE Ratio (TTM) | 21.78 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 4.55 (3.32%) |
Ex-Dividend Date | May 20, 2024 |
1y Target Est | N/A |
As a string of negative headlines and promising new developments present ideal buying opportunities for investors, Josh Lipton and Julie Hyman perform a mid-year check on the pharmaceutical industry. Goldman Sachs senior biotechnology analyst Chris Shibutani joins Market Domination to break down the health of the pharmaceutical large-caps and unrecognized areas of opportunity in the sector. Shibutani says the industry is "quite healthy," but acknowledges there are always "cross currents." He points to "tremendous advancements" in biotechnology innovation rising to daunting unmet needs, from cancer to cardiovascular disease. The analyst points to "holy grail-like" opportunities such as obesity drugs, and notes improvements in chemotherapy and next-generation antibody-drug conjugates for cancer treatment. However, Shibutani explains that the Inflation Reduction Act may challenge the industry, as the landmark legislation stipulates drug price negotiation for Medicare that is "beginning to play out." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
It is hard to get excited after looking at Johnson & Johnson's (NYSE:JNJ) recent performance, when its stock has...
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.